- Home
- LESL vs RIGL Comparison
LESL vs RIGL Comparison
Compare LESL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- RIGL
- Stock Information
- Founded
- LESL 1963
- RIGL 1996
- Country
- LESL United States
- RIGL United States
- Employees
- LESL N/A
- RIGL N/A
- Industry
- LESL Diversified Commercial Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LESL Miscellaneous
- RIGL Health Care
- Exchange
- LESL Nasdaq
- RIGL Nasdaq
- Market Cap
- LESL 538.1M
- RIGL 486.4M
- IPO Year
- LESL 2020
- RIGL 2000
- Fundamental
- Price
- LESL $1.42
- RIGL $20.09
- Analyst Decision
- LESL Hold
- RIGL Buy
- Analyst Count
- LESL 10
- RIGL 5
- Target Price
- LESL $2.83
- RIGL $34.80
- AVG Volume (30 Days)
- LESL 7.3M
- RIGL 223.6K
- Earning Date
- LESL 02-06-2025
- RIGL 03-04-2025
- Dividend Yield
- LESL N/A
- RIGL N/A
- EPS Growth
- LESL N/A
- RIGL N/A
- EPS
- LESL N/A
- RIGL 0.22
- Revenue
- LESL $1,331,389,000.00
- RIGL $157,374,000.00
- Revenue This Year
- LESL $4.80
- RIGL $51.34
- Revenue Next Year
- LESL $3.73
- RIGL $15.75
- P/E Ratio
- LESL N/A
- RIGL $91.32
- Revenue Growth
- LESL N/A
- RIGL 21.65
- 52 Week Low
- LESL $1.40
- RIGL $7.48
- 52 Week High
- LESL $8.05
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- LESL 30.34
- RIGL 45.75
- Support Level
- LESL $1.40
- RIGL $20.00
- Resistance Level
- LESL $1.59
- RIGL $21.93
- Average True Range (ATR)
- LESL 0.15
- RIGL 1.30
- MACD
- LESL -0.04
- RIGL -0.27
- Stochastic Oscillator
- LESL 2.17
- RIGL 2.01
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.